Malignancies in inflammatory bowel disease

References

• LBeaugerie. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? Gut 2012;61:476–83.
   PubMed Web of Science ®Google Scholar
• UNieminen, AJussila, SNordling, HMustonen, MAFärkkilä. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. Int J Cancer 2014;134:189–96.
   PubMed Web of Science ®Google Scholar
• SSebastian, VHernández, PMyrelid, RKariv, ETsianos, MToruner, et al. Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). J Crohns Colitis 2014;8:5–18.
   PubMed Web of Science ®Google Scholar
• MWLutgens, MGvan Oijen, GJvan der Heijden, FPVleggaar, PDSiersema, BOldenburg. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013;19:789–99.
   PubMed Web of Science ®Google Scholar
• ABergquist, AEkbom, ROlsson, DKornfeldt, LLööf, ADanielsson, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321–7.
   PubMed Web of Science ®Google Scholar
• SJStevens, EAVerschuuren, IPronk, Wvan Der Bij, MCHarmsen, THThe, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001;97:1165–71.
   PubMed Web of Science ®Google Scholar
• AKandiel, AGFraser, BIKorelitz, CBrensinger, JDLewis. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121–5.
   PubMed Web of Science ®Google Scholar
• LBeaugerie, NBrousse, AMBouvier, JFColombel, MLémann, JCosnes, CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617–25.
   PubMed Web of Science ®Google Scholar
• FMagro, LPeyrin-Biroulet, HSokol, XAldeger, ACosta, PDHiggins, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis 2014;8:31–44.
   PubMed Web of Science ®Google Scholar
• LPeyrin-Biroulet, KKhosrotehrani, FCarrat, AMBouvier, JBChevaux, TSimon, Cesame Study Group. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621–8.
   PubMed Web of Science ®Google Scholar
• MDLong, CFMartin, CAPipkin, HHHerfarth, RSSandler, MDKappelman. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143:390–9.
   PubMed Web of Science ®Google Scholar
• Jussila A1, Virta LJ, Pukkala E, Färkkilä MA. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol 2013;48:1405–13.
   PubMed Web of Science ®Google Scholar
• LBeaugerie, FCarrat, JFColombel, AMBouvier, HSokol, ABabouri, CESAME Study Group. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014;63:1416–23.
   PubMed Web of Science ®Google Scholar
• BCrohn, HRosenberg. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci 1925;170:220–8.
   Google Scholar
• JAEaden, KRAbrams, JFMayberry. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526–35.
   PubMed Web of Science ®Google Scholar
• PMunkholm, EVLoftusJr, AReinacher-Schick, AKornbluth, UMittmann, BEsendal. Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates. Digestion 2006;73:11–19.
   PubMed Web of Science ®Google Scholar
• LLakatos, GMester, ZErdelyi, GDavid, TPandur, MBalogh, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006;12:205–11.
   PubMed Web of Science ®Google Scholar
• TJess, EVLoftusJr, FSVelayos, WSHarmsen, ARZinsmeister, TCSmyrk, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. Gastroenterology 2006;130:1039–46.
   PubMed Web of Science ®Google Scholar
• KVWinther, TJess, ELangholz, PMunkholm, VBinder. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2:1088–95.
   PubMed Web of Science ®Google Scholar
• MDRutter, BPSaunders, KHWilkinson, SRumbles, GSchofield, MAKamm, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130:1030–8.
   PubMed Web of Science ®Google Scholar
• TJess, JSimonsen, KTJorgensen, BVPedersen, NMNielsen, MFrisch. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012;143:375–81.
   PubMed Web of Science ®Google Scholar
• AEkbom, CHelmick, MZack, HOAdami. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 1990;336:357–9.
   PubMed Web of Science ®Google Scholar
• CNBernstein, JFBlanchard, EKliewer, AWajda. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854–62.
   PubMed Web of Science ®Google Scholar
• PManninen, ALKarvonen, HHuhtala, PAitola, MHyöty, INieminen, et al. The risk of colorectal cancer in patients with inflammatory bowel diseases in Finland: a follow-up of 20 years. J Crohns Colitis 2013;7:551–7.
   PubMedGoogle Scholar
• MDKappelman, DKFarkas, MDLong, RErichsen, RSSandler, HTSorensen, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol 2014;12:265–73.
   PubMed Web of Science ®Google Scholar
• TJess, MGamborg, PMatzen, PMunkholm, TISorensen. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100:2724–9.
   PubMed Web of Science ®Google Scholar
• CCanavan, KRAbrams, JMayberry. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther 2006;23:1097–104.
   PubMed Web of Science ®Google Scholar
• ACvon Roon, GReese, JTeare, VConstantinides, AWDarzi, PPTekkis. The risk of cancer in patients with Crohn’s disease. Dis Colon Rectum 2007;50:839–55.
   PubMed Web of Science ®Google Scholar
• LEgan, RD’Inca, TJess, GPellino, FCarbonnel, BBokemeyer, et al. Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (II). J Crohns Colitis 2014;8:19–30.
   PubMed Web of Science ®Google Scholar
• TJess, CRungoe, LPeyrin-Biroulet. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10:639–45.
   PubMed Web of Science ®Google Scholar
• SSöderlund, FGranath, OBroström, PKarlén, RLöfberg, AEkbom, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology 2010;138:1697–703.
   PubMed Web of Science ®Google Scholar
• JAskling, PWDickman, PKarlén, OBroström, ALapidus, RLöfberg, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001;120:1356–62.
   PubMed Web of Science ®Google Scholar
• HJayaram, JSatsangi, RWChapman. Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction? Gut 2001;48:430–4.
   PubMed Web of Science ®Google Scholar
• RMSoetikno, OSLin, PAHeidenreich, HSYoung, MOBlackstone. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56:48–54.
   PubMed Web of Science ®Google Scholar
• UBroomé, ABergquist. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006;26:31–41.
   PubMed Web of Science ®Google Scholar
• MRutter, BSaunders, KWilkinson, SRumbles, GSchofield, MKamm, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451–9.
   PubMed Web of Science ®Google Scholar
• RBGupta, NHarpaz, SItzkowitz, SHossain, SMatula, AKornbluth, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133:1099–105.
   PubMed Web of Science ®Google Scholar
• SNGyde, PPrior, RNAllan, AStevens, DPJewell, SCTruelove, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988;29:206–17.
   PubMed Web of Science ®Google Scholar
• BLevin. Ulcerative colitis and colon cancer: biology and surveillance. J Cell Biochem Suppl 1992;16G:47–50.
   PubMedGoogle Scholar
• SSöderlund, LBrandt, ALapidus, PKarlén, OBroström, RLöfberg, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009;136:1561–7.
   PubMed Web of Science ®Google Scholar
• AEkbom, CHelmick, MZack, HOAdami. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228–33.
   PubMed Web of Science ®Google Scholar
• DPinczowski, AEkbom, JBaron, JYuen, HOAdami. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994;107:117–20.
   PubMed Web of Science ®Google Scholar
• JEaden, KAbrams, AEkbom, EJackson, JMayberry. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145–53.
   PubMed Web of Science ®Google Scholar
• TJess, EVLoftusJr, FSVelayos, KVWinther, WJTremaine, ARZinsmeister, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county. Minnesota. Am J Gastroenterol 2007;102:829–36.
   PubMed Web of Science ®Google Scholar
• JGong, LZhu, ZGuo, YLi, WZhu, NLi, et al. Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. PLoS One 2013;8:e81487.
   PubMed Web of Science ®Google Scholar
• TJess, ALopez, MAndersson, LBeaugerie, LPeyrin-Biroulet. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol 2014; Epub ahead of print.
   Web of Science ®Google Scholar
• FDvan Schaik, MGvan Oijen, HMSmeets, GJvan der Heijden, PDSiersema, BOldenburg. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012;61:235–40.
   PubMed Web of Science ®Google Scholar
• FBeigel, ASteinborn, FSchnitzler, CTillack, SBreiteneicher, JMJohn, et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf 2014;23:735–44.
   PubMed Web of Science ®Google Scholar
• NNyboe Andersen, BPasternak, SBasit, MAndersson, HSvanström, SCaspersen, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 2014;311:2406–13.
   PubMed Web of Science ®Google Scholar
• FSVelayos, EVLoftusJr, TJess, WSHarmsen, JBida, ARZinsmeister, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006;130:1941–9.
   PubMed Web of Science ®Google Scholar
• AJGreenstein, DBSachar, HSmith, APucillo, AEPapatestas, IKreel, et al. A comparison of cancer risk in Crohn’s disease and ulcerative colitis. Cancer 1981;48:2742–5.
   PubMed Web of Science ®Google Scholar
• SRCairns, JHScholefield, RJSteele, MGDunlop, HJThomas, GDEvans, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666–89.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (UK). Colonoscopic Surveillance for Prevention of Colorectal Cancer in People with Ulcerative Colitis, Crohn’s Disease or Adenomas. NICE clinical guideline No. 118 London: 2011.
   Google Scholar
• AKShergill, FAFarraye. Toward a consensus on endoscopic surveillance of patients with colonic inflammatory bowel disease. Gastrointest Endosc Clin N Am 2014;24:469–8.
   PubMedGoogle Scholar
• PDCollins, CMpofu, AJWatson, JMRhodes. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006:CD000279.
   Google Scholar
• VAnnese, MDaperno, MDRutter, AAmiot, PBossuyt, JEast, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohn’s Colitis 2013;7:982–1018.
   Google Scholar
• JDLewis, WBBilker, CBrensinger, JJDeren, DJVaughn, BLStrom. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080–7.
   PubMed Web of Science ®Google Scholar
• RGArmstrong, JWest, TRCard. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010;105:1604–9.
   PubMed Web of Science ®Google Scholar
• NKhan, AMAbbas, GRLichtenstein, EVLoftusJr, LABazzano. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 2013;145:1007–15.
   PubMed Web of Science ®Google Scholar
• LPeyrin-Biroulet, PDeltenre, Nde Suray, JBranche, WJSandborn, JFColombel. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644–53.
   PubMed Web of Science ®Google Scholar
• CASiegel, SMMarden, SMPersing, RJLarson, BESands. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874–81.
   PubMed Web of Science ®Google Scholar
• LJHerrinton, LLiu, XWeng, JDLewis, SHutfless, JEAllison. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011;106:2146–53.
   PubMed Web of Science ®Google Scholar
• AEkbom, CHelmick, MZack, HOAdami. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67:2015–19.
   PubMed Web of Science ®Google Scholar
• JSMaddox, KSoltani. Risk of nonmelanoma skin cancer with azathioprine use. Inflamm Bowel Dis 2008;14:1425–31.
   PubMed Web of Science ®Google Scholar
• MDLong, HHHerfarth, CAPipkin, CQPorter, RSSandler, MDKappelman. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010;8:268–74.
   PubMed Web of Science ®Google Scholar
• HSingh, ZNugent, AADemers, CNBernstein. Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis 2011;17:1741–50.
   PubMed Web of Science ®Google Scholar
• AEkbom, CGHelmick, MZack, LHolmberg, HOAdami. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 1992;103:954–60.
   PubMed Web of Science ®Google Scholar
• JStewénius, IAdnerhill, HAnderson, GREkelund, CHFlorén, FTFork, et al. Incidence of colorectal cancer and all cause mortality in non-selected patients with ulcerative colitis and indeterminate colitis in Malmö, Sweden. Int J Colorectal Dis 1995;10:117–22.
   PubMed Web of Science ®Google Scholar
• PGPersson, OBernell, CELeijonmarck, BYFarahmand, GHellers, AAhlbom. Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 1996;110:1339–45.
   PubMed Web of Science ®Google Scholar
• TCard, RHubbard, RFLogan. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 2003;125:1583–90.
   PubMed Web of Science ®Google Scholar
• MRomberg-Camps, EKuiper, LSchouten, AKester, MHesselink-van de Kruijs, CLimonard, et al. Mortality in inflammatory bowel disease in the Netherlands 1991-2002: results of a population-based study: the IBD South-Limburg cohort. Inflamm Bowel Dis 2010;16:1397–410.
   PubMed Web of Science ®Google Scholar
• CPSelinger, JAndrews, OFDent, INorton, BJones, CMcDonald, et al. Cause-specific mortality and 30-year relative survival of Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2013;19:1880–8.
   PubMed Web of Science ®Google Scholar
• AJussila, LJVirta, EPukkala, MAFärkkilä. Mortality and causes of death in patients with inflammatory bowel disease: a nationwide register study in Finland. J Crohns Colitis 2014;8:1088–96.
   PubMed Web of Science ®Google Scholar
• TJess, LRiis, IVind, KVWinther, SBorg, VBinder, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007;13:481–9.
   PubMed Web of Science ®Google Scholar